Millions for Proteomics Research in the Peer Reviewed Medical Research Program
Millions for Proteomics Research in the Peer Reviewed Medical Research Program
How SomaLogic technologies can give your research programs an edge.
Topics Covered
- Overview of the Peer Reviewed Medical Research Program (PRMRP) and Congressionally Directed Medical Research Programs (CDMRP)
- Overview of SomaLogic technologies that can give your research programs an edge
- How the PRMRP application process is unique to other U.S. government grant programs
- “Best Practices” for a successful PRMRP application
Tammy Hicks
Tammy Hicks is the Associate Director for the Southeast U.S. for SomaLoigic and has over 24 years of experience leading, mentoring, and selling in the Life Sciences market. She has supported many sectors, including academic research centers, pharmaceutical companies, and diagnostic testing providers. Tammy’s understanding of research and how to translate research findings into practical, actionable information for patients and physicians alike has allowed her to assist with many projects that improve health outcomes and deepen our understanding of human biology.
Elizabeth Barrows
Elizabeth “Liz” Barrows is a federal funding consultant whose clients have secured in excess of $100M over the course of her 10+-year career. Liz’s in-depth knowledge of the Department of Defense (DoD) funding opportunities and needs has a basis in experience at the DoD, where she managed pharmaceutical research and development projects in, and reviewed proposals for, blood products, resuscitation fluids and analgesic drugs for the U.S. Army from 2004-2009. She has also worked with NASA and private industry on the development of biomedical sensors, robotics, in vitro diagnostics, and blood products. She holds a master’s degree in biomedical engineering.
Millions for Proteomics Research in the Peer Reviewed Medical Research Program
A presentation by Tammy Hicks and Elizabeth Barrows
More webinars
WebinarA proteomics signature of NASH
There is a high unmet need for non-invasive tests that can robustly and reliably assess NAFLD for diagnosis, prognosis, and monitoring purposes. Large-scale profiling of serum/plasma proteins (proteomics) increasingly demonstrates utility to identify changes that accurately reflect and predict disease states and outcomes, including the fibrosis component of NASH that is driven by disease activity and remains the most robust histological marker of prognosis.
WebinarEarly Detection, Risk Stratification, and Drug Target Identification in Pulmonary Arterial Hypertension with Plasma Proteomics
Pulmonary arterial hypertension is a rare condition that is clinically heterogenous and often diagnosed late in disease progression. Plasma proteomics offers the potential to diagnose earlier, risk-stratify patients, and identify new drug targets.
WebinarUsing non-hypothesized based approaches for biomarker development
Current biomarkers are only moderately predictive in identifying individuals with mild traumatic brain injury or concussion. Therefore, more accurate diagnostic markers are needed for sport-related concussion (SRC).